Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

NIH-funded study to assess biomarkers in the blood of TBI patients

Biomarkers in the bloodstream could provide physicians with a quick and accurate method of assessing the severity of traumatic brain injury (TBI) and helping deliver and monitor the results of therapies, such as progesterone treatment.

4 Aug 2011

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.

4 Aug 2011

Conference to focus on connection between fluid balance and hypertension

Each day we consume liquids in order to keep hydrated and maintain our body's fluid balance. But just as a water balloon can get overtaxed by too much liquid, the human body is negatively affected when it retains fluids because it is unable to eliminate them properly. One of the key variables influencing how much fluid we hold in our bodies is ordinary table salt.

3 Aug 2011

Researchers awarded $12M to study pathology of severe lung injury

Researchers at the University of Illinois at Chicago College of Medicine have been awarded more than $11.7 million to study the pathology of severe lung injury.

30 Jul 2011

Anesthetic agent isoflurane may treat intracerebral hemorrhage

The anesthetic agent isoflurane may be a useful treatment for intracerebral hemorrhage (ICH)—a type of stroke caused by bleeding inside the brain, reports a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

22 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

Latest advances in Alzheimer's research presented at AAIC 2011

This week, more than 5,000 scientists from around the world gathered in Paris to report the latest advances in Alzheimer's research at the Alzheimer's Association International Conference 2011.

20 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011

DARA's DB959 shows promise against type 2 diabetes

A new peroxisome proliferator activated receptor agonist currently in development, DB959, will most likely be administered orally once a day, according to a presentation made by researchers recently at the American Diabetes Association's 71st Scientific Sessions.

14 Jul 2011

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor.

13 Jul 2011

Two papers highlight therapeutic potential of human Sertoli cells

Two papers published in the current issue of Cell Transplantation, now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, highlight the therapeutic potential of human Sertoli cells that are present in the testes and are also called "nurse" or "mother" cells because they nurture the developing sperm cells.

12 Jul 2011

Pregnant women face higher risk of stroke

High blood pressure during pregnancy is a leading cause of maternal and fetal mortality worldwide.

8 Jul 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Edema News and Research

Further Reading

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

NIH-funded study to assess biomarkers in the blood of TBI patients

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Conference to focus on connection between fluid balance and hypertension

Researchers awarded $12M to study pathology of severe lung injury

Anesthetic agent isoflurane may treat intracerebral hemorrhage

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

FDA approves Cephalon's REMS for FENTORA, ACTIQ

AMAG enters definitive merger agreement with Allos Therapeutics

Latest advances in Alzheimer's research presented at AAIC 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

DARA's DB959 shows promise against type 2 diabetes

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Two papers highlight therapeutic potential of human Sertoli cells

Pregnant women face higher risk of stroke

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News